Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Go back to Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 17.72 +0.42 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.30 | 52 Week High | $19.75 | |||
| Open | $17.73 | 52 Week Low | $4.26 | |||
| Day High | $18.10 | P/E | N/A | |||
| Day Low | $17.42 | EPS | $0.00 | |||
| Volume | 6,134,953 | |||||
